EUVIMEDEUVIMED entdecken
Crossref

Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF V600E -Mutated Anaplastic Thyroid Carcinoma

Sarah Hamidi iD, Priyanka C Iyer, Ramona Dadu, Maria K Gule-Monroe, Anastasios Maniakas iD, Mark E Zafereo iD, Jennifer R Wang iD, Naifa L Busaidy, Maria E Cabanillas

Thyroid® · 2024-03 · 34 (3) · 336-346

DOI: 10.1089/thy.2023.0573 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thyroid®, online erschienen am 16.01.2024. Verfasst von Sarah Hamidi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Thyroid Carcinoma, Anaplastic, Thyroid Neoplasms, Imidazoles, Pyridones. Die Arbeit wurde bisher 92-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The dabrafenib plus trametinib combination (DT) has revolutionized the treatment of BRAF V600E -mutated anaplastic thyroid carcinoma (BRAFm-ATC). However, patients eventually develop resistance and progress. Single-agent anti-PD-1 inhibitor spartalizumab has shown a median overall survival (mOS) of 5.9 months. Combination of immunotherapy with BRAF/MEK inhibitors (BRAF/MEKi) seems to improve outcomes compared with BRAF/MEKi alone, although no direct comparison is available. BRAF-targeted therapy before surgery (neoadjuvant approach) has also shown improvement in survival. We studied the efficacy and safety of DT plus pembrolizumab (DTP) compared with current standard-of-care DT alone as an initial treatment, as well as in the neoadjuvant setting.

Methods

Retrospective single-center study of patients with BRAFm-ATC treated with first-line BRAF-directed therapy between January 2014 and March 2023. Three groups were evaluated: DT, DTP (pembrolizumab added upfront or at progression), and neoadjuvant (DT before surgery, and pembrolizumab added before or after surgery). The primary endpoint was mOS between DT and DTP. Secondary endpoints included median progression-free survival (mPFS) and response rate with DT versus DTP as initial treatments, and the exploratory endpoint was mOS in the neoadjuvant group.

Results

Seventy-one patients were included in the primary analysis: n =23 in DT and n =48 in DTP. Baseline demographics were similar between groups, including the presence of metastatic disease at start of treatment ( p =0.427) and prior treatments with surgery ( p =0.864) and radiation ( p =0.678). mOS was significantly longer with DTP (17.0 months [confidence interval CI, 11.9–22.1]) compared with DT alone (9.0 months [CI, 4.5–13.5]), p =0.037. mPFS was also significantly improved with DTP as the initial treatment (11.0 months [CI, 7.0–15.0]) compared with DT alone (4.0 months [CI, 0.7–7.3]), p =0.049. Twenty-three patients were in the exploratory neoadjuvant group, where mOS was the longest (63.0 months [CI, 15.5–110.5]). No grade 5 adverse events (AEs) occurred in all three cohorts, and 32.4% had immune-related AEs, most frequently hepatitis and colitis.

Conclusions

Our results show that in BRAFm-ATC, addition of pembrolizumab to dabrafenib/trametinib may significantly prolong survival. Surgical resection of the primary tumor after initial BRAF-targeted therapy in selected patients may provide further survival benefit. However, conclusions are limited by the retrospective nature of the study. Additional prospective data are needed to confirm this observation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid Carcinoma, AnaplasticThyroid NeoplasmsImidazolesPyridonesPyrimidinonesHumansRetrospective StudiesProto-Oncogene Proteins B-rafProspective StudiesAntineoplastic Combined Chemotherapy ProtocolsOximesProtein Kinase InhibitorsMutation

Stichwörter der Autor:innen

BRAFV600Eanaplastic thyroid carcinomadabrafenibimmunotherapyneoadjuvanttrametinib

Substanzen

dabrafenibtrametinibProto-Oncogene Proteins B-rafOximesProtein Kinase InhibitorsBRAF protein, humanImidazolesPyridonesPyrimidinones

Autor:innen und Institutionen

  • Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Head & Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Sarah Hamidi, Anastasios Maniakas, Mark E Zafereo, Jennifer R Wang

Zitieren

APA

Hamidi, S., Iyer, P. C., Dadu, R., Gule-Monroe, M. K., Maniakas, A., Zafereo, M. E., Wang, J. R., Busaidy, N. L., & Cabanillas, M. E. (2024). Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF V600E -Mutated Anaplastic Thyroid Carcinoma. Thyroid®, 34(3), 336-346. https://doi.org/10.1089/thy.2023.0573

Vancouver

Hamidi S, Iyer PC, Dadu R, Gule-Monroe MK, Maniakas A, Zafereo ME, et al. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF V600E -Mutated Anaplastic Thyroid Carcinoma. Thyroid®. 2024;34(3):336-346. doi:10.1089/thy.2023.0573

BibTeX
@article{Hamidi2024,
  author = {Hamidi, Sarah and Iyer, Priyanka C and Dadu, Ramona and Gule-Monroe, Maria K and Maniakas, Anastasios and Zafereo, Mark E and Wang, Jennifer R and Busaidy, Naifa L and Cabanillas, Maria E},
  title = {Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF V600E -Mutated Anaplastic Thyroid Carcinoma},
  journal = {Thyroid®},
  year = {2024},
  volume = {34},
  number = {3},
  pages = {336--346},
  doi = {10.1089/thy.2023.0573}
}
Kostenlos starten →